TargaZyme, with a valuation of $196 million, is raising funds on StartEngine. The company is pioneering the development of cancer medicine that harnesses the power of the patient’s own immune system. The company is in the R&D stage and trying to eliminate chemotherapies, radiation, radical surgery, and other toxic drugs as treatments for cancer. The novel patented medicine of TargaZyme, TZ101, has shown to improve survival rates of cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant. Lynnet Koh founded TargaZyme in November 2005. The current crowdfunding campaign has a minimum target of $9,996.20 and a maximum target of $1,069,997.22. The campaign proceeds will be used to enable the delivery of cancer cures, further development of additional cures, and generate multiple revenue streams.